Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (633)	1/29/2005 12:50:31 AM
From: richardred	Read Replies (1) \| Respond to of 7243

Mylan Pain Patch Approved by FDA Friday January 28, 6:32 pm ET FDA Approves Mylan's Generic Version of Duragesic Pain Relief Patch Made by J&J PITTSBURGH (AP) -- Mylan Laboratories Inc. said Friday that regulators approved its application to sell a generic version of the Duragesic pain patch made by Johnson & Johnson unit Alza Corp. Mylan will begin shipping the product -- known chemically as fentanyl -- immediately. The drug maker said it will provide the patch in strengths that deliver 25 microgams, 50 micrograms, 75 micrograms or 100 micrograms an hour. Duragesic is approved by the Food and Drug Administration to treat chronic pain that cannot be managed by acetaminophen or similar therapies. The FDA first approved Mylan to sell the drug in November 2003, then rescinded the approval in July after a federal court ruled that Mylan had infringed on Alza's patent. Shares of Mylan closed down 4 cents at $16.60, then rose 39 cents, or 2.4 percent, to $16.99 in recent after-hours activity. Johnson & Johnson shares closed up 40 cents at $64.62. Shares of both companies are listed on the New York Stock Exchange. biz.yahoo.com